Fixed Dose Combination of Voglibose & Repaglinide in the Management of Postprandial Hyperglycemia in Indian Subjects

To evaluate the efficacy and tolerability of fixed dose combination of voglibose and repaglinide in postprandial hyperglycemia (PPHG) in Indian subjects. A non-randomized, open labeled, non-comparative, single-centric, study was conducted in total of 20 type 2 diabetes mellitus (T2DM) patients (9 men and 11 women, mean age 69.07 ± 3.495 years). Each patient was administered a fixed dose combination of voglibose 0.3mg and repaglinide 0.5/1mg three times a day, just before each meal for 30 days. Fasting blood glucose (FBG) and postprandial blood glucose (PPBG) was performed at baseline and at the end of study as assessment tools. At the end of study data was extractable only in 15 patients because 5 patient dropped out as they did not turn up for follow up at day 30.Postprandial blood glucose reduced significantly {-61.67mg/dl (95% confidence interval -76.79 to -46.54 p<0.0001)} from baseline at day 30. Also a significant reduction (p<0.0001) was found with FBG {-42.13mg/dl (Confidence interval -61.25 to -23.02 P value <0.0001)} at end of day 30. There were no adverse events reported including hypoglycemia. Voglibose and Repaglinide combination was effective and safe for the management of PPHG in T2DM patients.